Contineum Therapeutics, Inc. 8-K Filing
Ticker: CTNM · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1855175
| Field | Detail |
|---|---|
| Company | Contineum Therapeutics, Inc. (CTNM) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Contineum Therapeutics, Inc. (ticker: CTNM) to the SEC on Nov 20, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar).
How long is this filing?
Contineum Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 452 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-11-20 16:07:30
Key Financial Figures
- $0.001 — tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar
Filing Documents
- ctnm20251117_8k.htm (8-K) — 27KB
- ex_889569.htm (EX-99.1) — 9KB
- logo.jpg (GRAPHIC) — 8KB
- 0001437749-25-035860.txt ( ) — 182KB
- ctnm-20251120.xsd (EX-101.SCH) — 3KB
- ctnm-20251120_def.xml (EX-101.DEF) — 12KB
- ctnm-20251120_lab.xml (EX-101.LAB) — 15KB
- ctnm-20251120_pre.xml (EX-101.PRE) — 12KB
- ctnm20251117_8k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated November 20, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2025 Contineum Therapeutics, Inc. By: /s/ Peter Slover Peter Slover Chief Financial Officer Principal Financial Officer and Principal Accounting Officer